Acute Respiratory Distress Syndrome Market Size is anticipated to increase by 2034, estimates DelveInsight

Posted on
by

Acute Respiratory Distress Syndrome Market Size is anticipated to increase by 2034, estimates DelveInsight

DelveInsight’s ‘Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Market Forecast–2034’ report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

Key Takeaways from the Acute Respiratory Distress Syndrome Market Research Report

  • The increase in Acute Respiratory Distress Syndrome market size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • According to DelveInsight’s estimates, the total Acute Respiratory Distress Syndrome incident population in the 7MM, was estimated to be approximately 956,568 cases, in 2022. These cases are projected to increase during the forecast period (2023-2034).
  • As per DelveInsight’s analysis, in 2022, among the EU4 and the UK, Germany accounted for highest Acute Respiratory Distress Syndrome incident population with nearly 168,861 cases, followed by France with approximately 62,080 cases. These cases are expected to change during the forecast period.
  • According to DelveInsight’s estimates, in 2022, Japan had approximately 43,054 total incident cases of ARDS, of which nearly 30% were mild, 47% were moderate, while 23% was severe.
  • The leading Acute Respiratory Distress Syndrome Companies working in the market include MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
  • Promising Acute Respiratory Distress Syndrome Pipeline Therapies in the various stages of development include MN-166 (ibudilast), EB05 (NI 0101), Remestemcel-L, Sabizabulin (Veru-111), Solnatide (AP301), PLX-PAD, AVTX-002 (CERC-002), Alteplase, Lucinactant (sinapultide), BIO-11006, MultiStem (HLCM051), ExoFlo (DB-001), Zavegepant (BHV-3500), Metablok (LSALT peptide), ILT101, and others.
  • April 2024: GEn1E Lifesciences- A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS). GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.
  • April 2024: Dompé Farmaceutici S.p.A- Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO).To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200).
  • April 2024:- MiNK Therapeutics- A Phase 1/2 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 or Influenza. A Phase 1/2 study of agenT-797 to treat moderate to severe acute respiratory distress syndrome (ARDS) secondary to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or influenza.
  • April 2024:- Dr. Behcet Uz Children’s Hospital- Protocol for Comparing Closed-loop syncHronization vErsuS convenTional Synchronization In sPontaneously Breathing Pediatric Patients (CHESTSIPP) – a Randomized Cross-over Study.

 

Discover which therapies are expected to grab the Acute Respiratory Distress Syndrome Market Share @ Acute Respiratory Distress Syndrome Market Outlook

 

Acute Respiratory Distress Syndrome Overview

ARDS is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury which leads to fluid build-up inside the tiny air sacs of the lungs, and surfactant breakdown.

 

Acute Respiratory Distress Syndrome Epidemiology Insights

The epidemiology section of Acute Respiratory Distress Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Acute Respiratory Distress Syndrome Severity-specific Cases
  • Total Acute Respiratory Distress Syndrome Incident Cases
  • Total Acute Respiratory Distress Syndrome Incident Cases by Risk Factors

 

Download the report to understand which factors are driving Acute Respiratory Distress Syndrome Epidemiology trends @ Acute Respiratory Distress Syndrome Epidemiological Insights

 

Acute Respiratory Distress Syndrome Treatment Landscape

Treatment of acute respiratory distress syndrome is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management.

 

Acute Respiratory Distress Syndrome Drugs Market

The Acute Respiratory Distress Syndrome Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Respiratory Distress Syndrome signaling in Acute Respiratory Distress Syndrome are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

To know more about Acute Respiratory Distress Syndrome treatment guidelines, visit @ Acute Respiratory Distress Syndrome Treatment Market Landscape

 

Acute Respiratory Distress Syndrome Emerging Drugs

  • EB05: Edesa Biotech
  • Alteplase (Actilyse): Boehringer Ingelheim/ Genentech
  • BIO-11006: BioMarck Pharmaceuticals
  • ExoFlo (DB-001): Direct Biologics

 

Acute Respiratory Distress Syndrome Market Outlook

The report’s outlook on the Acute Respiratory Distress Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Respiratory Distress Syndrome therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Hemophilia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Respiratory Distress Syndrome market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Respiratory Distress Syndrome Drugs Uptake

  • Remestemcel-L being developed by Mesoblast is an investigational therapy comprising culture-expanded MSCs derived from the bone marrow of an unrelated donor and is administered in a series of intravenous infusions. The therapy is believed to have immunomodulatory properties that make it able to counteract the inflammatory processes. Recently Remestemcel-L received Fast Track designation for SARS-COV-2 acute respiratory disease. The US FDA advised Mesoblast for additional clinical study in Covid-19 ARDS in addition to the completed clinical study to support an emergency use authorization (EUA). The company is developing the drug for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, and it Phase III as per company’s pipeline, though there is no recent update.
  • TP508, being developed by Chrysalis BioTherapeutics, is a GMP manufactured 23 amino acid peptide that represents a natural region of human thrombin that is released at the site of injury to initiate tissue revascularization, regeneration and repair. Preclinical data has demonstrated that TP508 mitigates radiation damage and pulmonary inflammation induced by viral, bacterial, and smoke injury. It binds receptors expressed on the surface of endothelial cells, stem cells, and certain inflammatory cells. Upon binding to these receptors, TP508 activates a signaling cascade that restores vascular function in endothelial cells, stimulates proliferation and mobilization of progenitor stem cells, and reduces inflammation. It is being developed as an injectable drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS or nuclear radiation. TP508 also activates stem cells to regenerate tissues and restore function. It has the advantage of potentially showing efficacy where previous candidate drugs have failed. The TP508 Nuclear Countermeasure Program funded by NIH and BARDA is being developed under the FDA Animal Rule program with potential approval as early as 2027.

 

Major Acute Respiratory Distress Syndrome Companies

Several ARDS companies working in the market include MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.

 

Learn more about the FDA-approved drugs for Acute Respiratory Distress Syndrome @ Drugs for Acute Respiratory Distress Syndrome Treatment

 

Scope of the Acute Respiratory Distress Syndrome Market Report

  • Coverage- 7MM
  • Acute Respiratory Distress Syndrome Companies- MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
  • Acute Respiratory Distress Syndrome Pipeline Therapies- MN-166 (ibudilast), EB05 (NI 0101), Remestemcel-L, Sabizabulin (Veru-111), Solnatide (AP301), PLX-PAD, AVTX-002 (CERC-002), Alteplase, Lucinactant (sinapultide), BIO-11006, MultiStem (HLCM051), ExoFlo (DB-001), Zavegepant (BHV-3500), Metablok (LSALT peptide), ILT101, and others.
  • Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome Market Drivers and Barriers
  • Acute Respiratory Distress Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Acute Respiratory Distress Syndrome Drugs in development @ Acute Respiratory Distress Syndrome Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. ARDS Market Overview at a Glance

4. ARDS Market: Future Perspective

5. Executive Summary of ARDS

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Off-Label Therapies for ARDS

11. Emerging Drugs

12 ARDS: The Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Reimbursement and Market Access

18. Unmet Needs

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/